Trials / Completed
CompletedNCT00757419
AZD3355 Dose-escalation Study in Healthy Males
A Phase 1 Single Centre Single-blind Randomised Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD3355 After Administration of Single Ascending Doses and Multiple Repeated Doses in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The aim is to establish the maximal tolerated dose of AZD3355 for the selection of doses in the up-coming studies. This will be done by comparing single and repeated doses of AZD3355 to placebo ("inactive substance"). Safety and tolerability variables will be closely monitored throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD3355 | capsules, oral, single or twice daily dose |
| DRUG | Placebo | To match dosing of AZD3355 |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-09-23
- Last updated
- 2010-12-07
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00757419. Inclusion in this directory is not an endorsement.